Showing results (11-20 of 29) with videos related to

Sort By:
Pageof 3
Obstetrics and Gynecology|February 17, 1998
Absence of estrogen and progesterone receptors in glassy cell carcinoma of the cervixI Atlas, W Gajewski, S Falkenberry, et al.
European Journal of Gynaecological Oncology|January 1, 1991
The use of minoxidil to attempt to prevent alopecia during chemotherapy for gynecologic malignanciesC O Granai, H Frederickson, W Gajewski, et al.
American Journal of Hematology|September 23, 1997
Prediction of therapy-related acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS) after autologous bone marrow transplant (ABMT) for lymphomaR D Legare, J G Gribben, M Maragh, et al.
Journal of Health and Human Services Administration|June 10, 2000
Screening workers for genetic hypersusceptibility: potential ethical, legal, and social implications from the Human Genome ProjectA C Wicks, L E Sever, R Harty, et al.
The Journal of Reproductive Medicine|October 1, 1996
Synchronous endometrioid tumors of the ovary and endometrium. A clinicopathologic study of 22 casesS S Falkenberry, M M Steinhoff, M Gordinier, et al.
Leukemia|February 3, 1998
CBFA2, frequently rearranged in leukemia, is not responsible for a familial leukemia syndromeR D Legare, D Lu, M Gallagher, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|October 9, 2002
Molecular analysis of inhibin A and activin A subunit gene loci in epithelial ovarian cancerS Depasquale, G Lambert-Messerlian, M R Quddus, et al.
Blood|June 17, 1998
Predictive value of clonality assays in patients with non-Hodgkin's lymphoma undergoing autologous bone marrow transplant: a single institution studyS Mach-Pascual, R D Legare, D Lu, et al.
Blood|June 15, 1996
Linkage of a familial platelet disorder with a propensity to develop myeloid malignancies to human chromosome 21q22.1-22.2C Y Ho, B Otterud, R D Legare, et al.
Breast Cancer Research and Treatment|June 4, 2021
Neoadjuvant weekly paclitaxel and carboplatin with trastuzumab and pertuzumab in HER2-positive breast cancer: a Brown University Oncology Research Group (BrUOG) studyM L Lopresti, J J Bian, B J Sakr, et al.
Pageof 3